| Acceptance rate | 46% |
|---|---|
| Time to first decision | 6 months* |
| Time to decision with review | 50 days* |
*Approximate number of days
**The days mentioned above are averages and do not indicate exact durations. The process may vary for each article.
ACTA Pharmaceutica Sciencia
2025 , Vol 63 , Num 1
The role of hypoxia-inducible factor 1 alpha and peroxisome proliferator activated receptor gamma coactivator 1 alpha in the diagnosis of breast cancer
1 Al-Nahrain University, College of Medicine, Department of Chemistry and Biochemistry, Baghdad, Iraq2 Al-Nahrain University, College of Medicine, Department of Surgery, Baghdad, Iraq
3 Ministry of Health and Environment, Oncology Teaching Hospital, Baghdad, Iraq
DOI : 10.23893/1307-2080.APS6304 Viewed : 84 - Downloaded : 31 This study aimed to assess the possible association between hypoxia-inducible factor 1 (HIF-?1) and proliferator activated receptor gamma coactivator 1 (PGC-?1) levels in early and advanced breast cancer patients and to study the correlation between these parameters in a case-control study conducted on 40 females with breast cancer categorized into early and advanced stages, with 20 patients in each group, collected from the Medical City and Oncology teaching hospital, Baghdad, Iraq, between June and October 2023. The levels of HIF-?1 and PGC-?1 were measured in the serum of breast cancer patients by ELISA technique and compared with 40 age- and gender- matched controls, which showed that the levels of HIF-1? and PGC-1? increased significantly in the early and advanced stages in comparison with controls, which indicates that the markers can be used as diagnostic markers for breast cancer in the early and advanced stages. Keywords : HIF-1?, PGC-1?, breast cancer, diagnostic markers